Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/05/19 06:09:35」(JST)

wiki en

Idarubicin /ˌaɪdəˈruːbɨsɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts itself into DNA and prevents DNA from unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.^[1] Similar to other anthracyclines, it also induces histone eviction from chromatin.^[2]

It belongs to the family of drugs called antitumor antibiotics.

It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia.

It is distributed under the trade names Zavedos (UK) and Idamycin (USA).

References

^ Package insert
^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications 4: 1908. doi:10.1038/ncomms2921. PMID 23715267.

External links

Idarubicin bound to proteins in the PDB

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. アントラサイクリン系化学療法剤の心毒性 cardiotoxicity of anthracycline like chemotherapy agents
2. 若年成人における急性骨髄性白血病に対する導入療法 induction therapy for acute myeloid leukemia in younger adults
3. 高齢者における急性骨髄性白血病の治療 treatment of acute myeloid leukemia in older adults
4. 再発性または難治性の急性骨髄性白血病の治療 treatment of relapsed or refractory acute myeloid leukemia
5. 化学療法の血管外漏出による傷害およびその他の非抗腫瘍薬による水疱 extravasation injury from chemotherapy and other non antineoplastic vesicants

English Journal

l-Cysteine capped Mn-doped ZnS quantum dots as a room temperature phosphorescence sensor for in-vitro binding assay of idarubicin and DNA.

Ertas N1, Satana Kara HE2.
Biosensors & bioelectronics.Biosens Bioelectron.2015 Aug 15;70:345-50. doi: 10.1016/j.bios.2015.03.055. Epub 2015 Mar 24.
l-cysteine capped Mn doped ZnS quantum dots/ Idarubicin (IDA) nanohybrids were used as novel room temperature phosphorescence (RTP) sensor to detect double stranded deoxyribonucleic acid (ds-DNA)/drug interaction. IDA, anthracycline derivative anticancer drug, was adsorbed on the surface of the QDs
PMID 25840021

All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.

Sanz MA1, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups.
Annals of hematology.Ann Hematol.2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15.
Front-line treatment of acute promyelocytic leukaemia (APL) consists of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. In this setting, a comparison of idarubicin and daunorubicin has never been carried out. Two similar clinical trials using ATRA and chemotherapy for newly diag
PMID 25975975

Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia.

Sanz MA1, Montesinos P, Casale MF, Díaz-Mediavilla J, Jiménez S, Fernández I, Fernández P, González-Campos J, González JD, Herrera P, de Lisa E, Olave T, Rojas R, Salamero O, Sayas MJ, Pellicer A, Perales A.
Annals of hematology.Ann Hematol.2015 Aug;94(8):1357-61. doi: 10.1007/s00277-015-2372-5. Epub 2015 Apr 25.
The management of pregnant women with acute promyelocytic leukemia (APL) is a challenge with limited evidence-based information available. We are reporting a series of 14 consecutive pregnant women with APL who were registered in the PETHEMA Data Centre between 1996 and 2012. APL was diagnosed durin
PMID 25911134

Japanese Journal

急性骨髄性白血病の寛解導入療法におけるイダルビシンvs.ダウノルビシン

大竹茂樹
血液内科 67(3), 376-382, 2013-09
NAID 40019830507

初発時に中枢神経浸潤を合併した急性前骨髄球性白血病

櫻井環,黒田裕行,山田充子,在原洋平,定免渉,平子匡,安部智之,藤井重之,前田征洋,藤田美悧,加藤淳二
臨床血液 54(6), 574-578, 2013
急性前骨髄球性白血病(APL)の初発時に中枢神経系(CNS)浸潤を伴うことはまれである。症例は58歳，男性で2010年3月に動悸・息切れ・高熱・羞明・意識障害のため入院となった。骨髄像と染色体分析からAPLと診断した。頭部MRIで多発する高信号領域と脳脊髄液細胞診でAPL細胞を認め，APLのCNS浸潤と判断された。All-trans retinoic acidと全身化学療法を行い，地固め療法終了後 …
NAID 130004501824

sorafenib で寛解に至った初期治療抵抗性FLT3-ITD陽性急性単芽球性白血病

高橋憲幸,川上貴子,佐藤裕子 [他],小野田正志,簡野美弥子,三井哲夫,早坂清
臨床血液 53(11), 1932-1936, 2012-11-30
症例は6歳男児。FLT3-ITD陽性急性単芽球性白血病(AMoL)と診断，日本小児白血病リンパ腫研究グループAML-05寛解導入で寛解に至らなかった。救済療法でも寛解に至らず，骨髄回復期にsorafenibを200 mg/日で開始，300 mg/日に増量，10日後寛解を得た。29日間内服後，HLA 2座不一致骨髄移植を施行。移植後71日目に骨髄再発，150mg/日を隔日投与で再開，部分寛解を得た。 …
NAID 10031131262

Related Pictures

★リンクテーブル★

リンク元	「アントラサイクリン」「イダルビシン」「IDR」
拡張検索	「idarubicin hydrochloride」

「アントラサイクリン」

Idarubicin
Systematic (IUPAC) name
	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxo-α-L-lyxo-hexopyranoside
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a691004
Pregnancy cat.	D (US)
Legal status	℞-only (US)
Pharmacokinetic data
Protein binding	97%
Half-life	22 hours
Identifiers
CAS number	58957-92-9
ATC code	L01DB06
PubChem	CID 42890
DrugBank	DB01177
ChemSpider	39117
UNII	ZRP63D75JW
KEGG	D08062
ChEBI	CHEBI:42068
ChEMBL	CHEMBL1117
Synonyms	9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
Chemical data
Formula	C26H27NO9
Mol. mass	497.494 g/mol
	SMILES O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@@](O)(C(=O)C)C[C@@H]5O[C@@H]4O[C@H]([C@@H](O)[C@@H](N)C4)C;
	InChI InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1 ; Key:XDXDZDZNSLXDNA-TZNDIEGXSA-N ;
(what is this?) (verify)